---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-303786"
form_type: "8-K"
ticker: "RPRX"
cik: "0001802768"
company_name: "Royalty Pharma plc"
filed_at: "2023-12-27T23:59:59+00:00"
generated_at: "2026-06-07T06:58:47.411442+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cytokinetics' aficamten Phase 3 success triggers $75M milestone for Royalty Pharma

## Summary
- Cytokinetics announced positive Phase 3 SEQUOIA-HCM results for aficamten in symptomatic obstructive HCM.
- Royalty Pharma holds a 4.5% global royalty on aficamten (3.5% on sales >$1B) as per Jan 2022 agreement.
- Royalty Pharma provided $50M commercial launch capital; Cytokinetics can now draw $75M milestone.
- Additional $100M milestone payable upon FDA acceptance of aficamten NDA.
- Full results to be presented at upcoming medical conference.

## SEC filing metadata
- accession: 0001193125-23-303786
- form_type: 8-K
- ticker: RPRX
- cik: 0001802768
- company_name: Royalty Pharma plc
- filed_at: 2023-12-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802768/000119312523303786/0001193125-23-303786-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802768/000119312523303786/d615272d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-303786
- JSON: https://secwatch.observer/filing/0001193125-23-303786.json
- Plain text: https://secwatch.observer/filing/0001193125-23-303786.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.